



BTOG Masterclass in Peri-Operative Therapies

Thursday 29th July 2021

17:30 to 18:30

Approved for 1 category 1 (external) CPD credit (code 136288)

**From the Federation of the Royal Colleges of
Physicians of the United Kingdom**

Chair: James Spicer

17:30 Adjuvant Targeted Therapies Alastair Greystoke

17:50 Q&A

18:00 Peri-operative Immunotherapy Samreen Ahmed

18:20 Q&A

18:30 Close

Declarations

1. BTOG confirms that all speakers will introduce themselves and will include as their 1st slide a declaration of conflict of interests and this will be visible to attendees.
2. BTOG confirms there will be a clear view of each speaker's slides. Each speaker will talk to the slides and their voice will accompany the slide discussion (where applicable).
3. BTOG confirms that participants viewing the educational presentations live will be able to submit questions and comments via live webinar chat.
4. BTOG confirms that if RCP approves this live webinar BTOG will provide access via BTOG's online resources and note that CPD will apply to the archived version for four weeks after the event date – we will ensure participants viewing the full archived version will be awarded the appropriate CPD and be issued a certificate of attendance.

Biographies

Professor Samreen Ahmed - I have been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine London. I have a research degree (MD) through Nottingham University and undertook Oncology training in Western Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. I am a Fellow of the Royal College of Physicians. I am Training Programme Director for Medical Oncology. I am the research Lead for both breast and lung cancer in the East Midlands Cancer Network. I work with the National Cancer Research Network as a trialist.

Dr Alastair Greystoke

Dr Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust. He is one of 3 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle, and has a special interest in the development of new anti-cancer drugs for patients with thoracic malignancies. In addition, he is the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in NSCLC), Clinical Lead for Cancer for the Yorkshire, Hull and North East England Genomic Laboratory Hub and he leads the Pharmacodynamic Biomarker team at the Northern Institute for Cancer Research, Newcastle University.

Professor James Spicer is professor of experimental cancer medicine, King's College London, and consultant in medical oncology, Guy's and St Thomas' Hospital NHS Foundation Trust. He runs the King's Health Partners cancer phase 1 trials programme and leads the King's Experimental Cancer Medicine Centre, funded by Cancer Research UK/National Institute for Health Research. James' interests include the development of new cancer drugs, and the care of patients with thoracic malignancies, including lung cancer and mesothelioma. His translational research focus is on novel immunotherapies.